Evidence map›Paper›PMID 28176928›Full record

ArticleDrug design, development and therapy2017

Jianhui Wu, Ming Zhao, Yuji Wang, Yaonan Wang, Haimei Zhu, Shurui Zhao, Lin Gui, Xiaoyi Zhang, Shiqi Peng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jianhui WuBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Ming ZhaoBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China; Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.
Yuji WangBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Yaonan WangBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Haimei ZhuBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Shurui ZhaoBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Lin GuiBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Xiaoyi ZhangBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Shiqi PengBeijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Capital Medical University · CNKaohsiung Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well documented that the surfaces of cancer cells, activated platelets and inflammatory cells are rich in P-selectin.

Indexed as

AnimalsAntineoplastic AgentsCarbolinesCell Line, TumorCell ProliferationDNADNA CleavageDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansInflammationMaleMiceMice, Inbred ICRMolecular Docking SimulationMolecular StructureAntineoplastic Agentscalf thymus DNACarbolinesDNAN-(3-hydroxymethyl-beta-carboline-1-yl-ethyl- 2-yl)-l-PhePhenylalanineanti-inflammationantithrombosisantitumornanomedicineP-selectin

Identifiers

PMID28176928
PMCPMC5265142
OpenAlexW2573951977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.